Beyond Proteinuria Control: Four Unmet Needs Defining the FSGS Landscape | REACH MarketVue® Amanda Theocles2026-06-29T15:07:13+00:00June 29th, 2026|MarketVue, Nephrology, Physician Insights, Press Release| Read More
Beyond Myotonia: What DM1 Patients and Physicians Really Need from a Novel Therapy | REACH MarketVue® Amanda Theocles2026-06-22T16:07:33+00:00June 25th, 2026|MarketVue, Neuromuscular, Physician Insights, Press Release| Read More
What It Will Take to Modify the Course of Huntington’s Disease | REACH MarketVue® Amanda Theocles2026-06-18T20:17:57+00:00June 19th, 2026|MarketVue, Neurology, Physician Insights, Press Release| Read More
First-Generation ASOs in Angelman Syndrome: A Promising Start, With Room to Improve | REACH MarketVue® Amanda Theocles2026-06-17T15:51:09+00:00June 18th, 2026|MarketVue, Neurology, Physician Insights, Press Release| Read More
Three Critical Gaps in Dravet Syndrome Care – and Why Genetic Therapy Changes Everything | REACH MarketVue® Amanda Theocles2026-06-16T16:44:12+00:00June 16th, 2026|MarketVue, Neurology, Physician Insights, Press Release| Read More
Fragile X Syndrome: Where Behavioral Control and Cognitive Gain Remain Out of Reach | REACH MarketVue® Amanda Theocles2026-06-15T16:50:05+00:00June 15th, 2026|MarketVue, Neurology, Physician Insights, Press Release| Read More
Three Critical Gaps Defining the Next Wave of Ovarian Cancer Therapy Amanda Theocles2026-06-08T17:39:16+00:00June 8th, 2026|MarketVue, Oncology, Physician Insights, Press Release| Read More
What the FSGS Market Shift Means for Commercial Strategy Amanda Theocles2026-06-10T18:59:03+00:00April 14th, 2026|MarketVue, Nephrology, Physician Insights| Read More
What We Can Expect from the Next Wave of ATTR-CM Therapies Amanda Theocles2026-06-10T18:55:55+00:00March 24th, 2026|Cardiology, MarketVue, Physician Insights| Read More
Systemic Lupus Erythematosus (SLE): A Market in Transition Amanda Theocles2026-06-10T18:53:03+00:00February 27th, 2026|Immunology, MarketVue, Physician Insights| Read More
